# An Early Stage Study to Evaluate Oba01 for Injection in Patients With DR5 Positive LA/mNSCLC

> **NCT06083870** · PHASE1 · RECRUITING · sponsor: **Lu Shun** · enrollment: 35 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer Metastatic

## Interventions

- **DRUG:** Oba01

## Key facts

- **NCT ID:** NCT06083870
- **Lead sponsor:** Lu Shun
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-12-13
- **Primary completion:** 2025-07
- **Final completion:** 2026-07
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2023-12-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06083870

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06083870, "An Early Stage Study to Evaluate Oba01 for Injection in Patients With DR5 Positive LA/mNSCLC". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06083870. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*